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Ca^2+^ influx through voltage-gated L-type Ca^2+^ channels (LTCCs)[2](#fn2){ref-type="fn"} regulates numerous physiological functions, including muscle contraction, hormone release, neuronal firing and plasticity, sensory function, and cardiac pacemaking ([@ref1]). Four pore-forming α1 subunit isoforms (Ca~V~1.1--Ca~V~1.4) with different biophysical properties and expression profiles evolved to adjust LTCC Ca^2+^ signals to cellular needs. Ca~V~1.3 channels play a unique role for hearing (sensory signaling in cochlear inner hair cells (IHC)) and sinoatrial node (SAN, diastolic depolarization) function ([@ref2]). Ca~V~1.3 channels appear ideally suited for these functions because the operating range of both IHCs and SAN cells is within a voltage range of about --60 and --40 mV where these channels can conduct inward current because of their negative activation range (Refs. [@ref3]--[@ref5] and for review see Ref. [@ref6]). In neurons, Ca~V~1.3 channels also serve pacemaker function and shape neuronal firing ([@ref7], [@ref8]). Ca^2+^ influx through LTCCs is limited by a Ca^2+^-dependent feedback mechanism, the so-called calcium-dependent inactivation (CDI) ([@ref9]). CDI develops in response to local or global elevations of intracellular Ca^2+^ sensed by channel-bound calmodulin ([@ref10], [@ref11]). However, moderation of CDI is an important prerequisite in some cells, such as in IHCs (Ca~V~1.3; 12--14) and in retinal photoreceptors (Ca~V~1.4), where slow inactivation of *I*~Ca~ is required for sensory signaling. In Ca~V~1.4 channels, CDI is completely prevented by an intrinsic gating modulator located in the Ca~V~1.4α1 C terminus, and CDI is restored in C-terminal truncation mutants ([@ref15], [@ref16]). This C-terminal gating modulator (CTM) not only prevents CDI but also shifts the activation voltage range to more positive potentials ([@ref15]). Gating modulation seems not to be limited to Ca~V~1.4 because co-expression of C-terminal fragments of Ca~V~1.2 channels also shifts their activation range to more positive voltages and inhibits pore opening ([@ref17]). Because C termini of Ca~V~1.2 (and also Ca~V~1.1) α1 subunits are proteolytically cleaved ([@ref18]--[@ref20]) but remain noncovalently bound to proximal C-terminal domains, they may serve as autoinhibitory modules ([@ref17], [@ref21]).

We hypothesized that Ca~V~1.3 function may also be fine-tuned by a CTM domain similar to Ca~V~1.1, Ca~V~1.2, and Ca~V~1.4. Unlike for other LTCC α1 subunits, alternative splicing generates Ca~V~1.3 α1 subunits with long (usage of exon 42, Ca~V~1.3~42~) or short (usage of exon 42A, Ca~V~1.3~42A~) C termini. A CTM would therefore confer different biophysical properties on Ca~V~1.3 only if present as in certain (*i.e.* long) variants.

Here we provide unequivocal evidence that an intramolecular protein-protein interaction gives rise to substantial gating differences between Ca~V~1.3~42~ and Ca~V~1.3~42A~. Our finding that the long and the short splice variants are expressed in several mouse and human tissues suggests that both contribute to fine-tuning of physiological Ca~V~1.3 channel function.

EXPERIMENTAL PROCEDURES
=======================

Cloning of cDNA Constructs
--------------------------

To generate splice variant Ca~V~1.3~42A~, the alternatively spliced exon 42A was introduced into Ca~V~1.3 cDNA (Ca~V~1.3~42~ = human Ca~V~1.3~8A~ as in Ref. [@ref4], GenBank™ accession number EU363339) by co-ligating an EcoRI-BamHI-cut PCR product containing exon 42A from a rat brain α1 subunit (GenBank™ accession number M57682) with HindIII-EcoRI-cut Ca~V~1.3 cDNA into HindIII-BamHI (4622--7100)-cut Ca~V~1.3-pBS vector. The rat exon 42A amino acid sequence is identical to its human homologue. Human Ca~V~1.3 containing exon 42A was subsequently cloned into vector pGFP^--^ (wild type) short form of the Ca~V~1.3 protein ([@ref4]). For analyzing the effects of exon 44, amino acid residues RTRYYETYI were introduced into an untagged construct containing the long Ca~V~1.3 C terminus after position 1787 using standard PCR techniques. Ca~V~1.3~ΔC473~, Ca~V~1.3~ΔC158~, Ca~V~1.3~ΔC116~, and Ca~V~1.3~ΔC76~ channels were constructed by introducing stop codons into untagged Ca~V~1.3~42~ at respective amino acid positions 1665, 1980, 2022, and 2062 followed by artificial restriction sites as follows: BamHI\* for Ca~V~1.3~ΔC158~ and Ca~V~1.3~ΔC76~, HpaI\* for Ca~V~1.3~ΔC116~, and XhoI\* for Ca~V~1.3~ΔC473~. Peptides GFP-C~158~, GFP-C~116~, and GFP-C~76~ were constructed by ligating HindIII\*-SalI\*-flanked PCR products corresponding to amino acids 1980--2137, 2022--2137, and 2062--2137 of Ca~V~1.3~42~ into the pGFP^+^ plasmid resulting in the corresponding GFP-tagged Ca~V~1.3 C-terminal peptides ([@ref22]). For FRET analysis, all C-terminal Ca~V~1.3 fragments were cloned either into the mammalian expression vector *pEYFP-C1* for N-terminal EYFP labeling or vector *pECFP-N1* for C-terminal enhanced CFP labeling (Clontech). N-terminally EYFP-labeled constructs 5′-HindIII\* and 3′-SalI\* restriction sites flanking nucleotide sequences corresponding to the following Ca~V~1.3 amino acid positions were introduced and cloned into HindIII-SalI-cut vector *pEYFP-C1* as follows: peptide EF-preIQ-IQ-postIQ, amino acids 1453--2137; EF-preIQ-IQ, amino acids 1453--1623; and EF-preIQ-IQ-PCRD, amino acids 1453--1664. To construct peptide EF-preIQ-IQ-PCRD^RRQQ^, arginines at positions 1640 and 1641 were mutated to glutamines by splicing by overlapping extension-PCR. For C~158~-CFP and C~116~-CFP, 5′-EcoRI\* and 3′-BamHI\* restriction sites were introduced to flanking nucleotide sequences corresponding to Ca~V~1.3 amino acid positions 1980--2137 and 2022--2137 and cloned into EcoRI-BamHI-cut vector *pECFP-N1*. To generate enhanced CFP-C~116~^DEQQ^, aspartate and glutamate at positions 2073 and 2076 were mutated to glutamines by splicing by overlapping extension-PCR. Integrity of all constructs was confirmed by DNA sequencing (MWG Biotec, Martinsried, Germany). Construct Ca~V~1.3~42~ was subjected to full-length sequence analysis. Numbering of amino acids or nucleotide positions in all constructs refers to GenBank™ accession number EU363339. Asterisks indicate artificial restriction sites introduced by PCR.

Qualitative RT-PCR
------------------

Mouse tissue was prepared from C57B/6N wild-type mice. Total RNA was isolated from whole-brain and brain sub-regions using the RNAqueos®-4PCR kit (Ambion, Foster City, CA). After DNase I treatment, RNA integrity was checked by the quality of the 28 S and 18 S rRNA bands on a denaturing agarose gel. Organ of Corti mRNA was prepared from P4 or P19 mice as described in Ref. [@ref23]. Human total RNAs from brain, heart, pancreas, and retina were purchased from Clontech. One μg of total RNA was used for first strand cDNA synthesis by reverse transcriptase (RevertAid™ H Minus First Strand cDNA synthesis kit, MBI; Fermentas, Hanover, Germany) and random hexamer primers. For PCR analysis, the forward (fwd) primer was located in exon 39 (GenBank™ accession number NM_028981 for mouse and EU363339 for human). To differentiate between Ca~V~1.3~42~ and Ca~V~1.3~42A~, specific reverse (rev) primers were designed, located either in exon 42 or 42A. The following primers were used for mouse: fwd primer, 5′-CAACCCTGTTTGCTTTGGTC-3′, and rev primer for exon 42, 5′TATAGCCCGTCGGATTTCTG-3′ (332-bp product); rev primer for exon 42A, 5′-CTTCCTTCCGGAGGAGTGC-3′ (483-bp product). The following primers were used for human: fwd primer, 5′-AACCCTGTTTGCTTTGGTTC-3′, rev primer for exon 42, 5′-TATAGCACGCCGGATTTCTG-3′ (331-bp product); rev primer for exon 42A, 5′-CCACCTTCCGGAGGAGTG-3′ (488-bp product). In mouse organ of Corti, splice variants were also detected with the following primer pairs: exon 42 fwd primer, 5′-CTGCTTGACCAAGTTGTCCCTCCA-3′, rev primer, 5′-CTACAAGGTGGTAATGCAAATCAT-3′; exon 42A, fwd primer, 5′-CGCGGATCCTACTTGACCAAGTTGTCCC-3′; rev primer, 5′-CGCAAGCTTCTAGAGCATCCGTTCAAGC-3′. Mouse and human GAPDH was used as positive control as follows: for mouse (GenBank™ accession number NM_008084), fwd primer, 5′-ACTCCACTCACGGCAAATTC-3′, rev primer 5′-CACATTGGGGGTAGGAACAC-3′ (572-bp product); for human (GenBank™ accession number NM_002046), fwd primer, CAATGACCCCTTCATTGACC, rev primer, 5′-GAGGCAGGGATGATGTTCTG-3′ (531-bp product). 500 ng (2.7 μg for organ of Corti) of reverse-transcribed cDNA was used as template for each PCR. Samples without template were used as contamination control. The following PCR program was used: 94 °C for 3 min, 40 cycles of 94 °C for 45 s, 55 °C for 45 s, and 68 °C for 1 min, followed by an elongation step of 68 °C for 10 min. PCRs were performed using BioTherm™ TaqDNA polymerase (GeneCraft, Lüdinghausen, Germany) in the presence of 1.5 m[m]{.smallcaps} MgCl~2~. The resulting PCR products were subcloned into pGEM-T Easy vectors (Promega, Mannheim, Germany) and sequenced.

Quantitative RT-PCR
-------------------

*RNA Isolation and cDNA Preparation*---Tissue from three adult male c57BL/6N mice (3--6 months) was used for whole-brain and brain sub-region cDNA preparations. Total RNA and cDNA were prepared as described ([@ref24]).

*Quantitative RT-PCR*---The relative abundance of different Ca~V~1.3 mRNAs was assessed by TaqMan quantitative PCR (50 cycles) using a standard curve method as described ([@ref24]). TaqMan gene expression assays, designed to span exon-exon boundaries, were purchased from Applied Biosystems (Foster City, CA). Assessment of mouse GAPDH transcripts was included as efficiency reference. Assay identification numbers are as follows: exon 42, Mm0551393_m1 (efficiency (*E*) = 103.6%); exon 42A (*E* = 98.7%), custom-designed (fwd primer, 5′-GGAAGTACCCTGCGAAGAACAC-3′; probe, 5′-TTGCCCTACAGATGCTTG-3′; rev primer, 5′-CTCAGGCAGAGAACTCTAAAGCAT-3′); GAPDH, Mm99999915_g1. To amplify specific cDNA templates from the analyzed tissues for the standard curves of each assay, primer pairs were as follows: exon 42 fwd primer, 5′-CAACCCTGTTTGCTTTGGTC-3′, rev primer, 5′-TGATTGACATGGTTTCCAAGC-3′; exon 42A fwd primer, 5′-CAACCCTGTTTGCTTTGGTC-3′, rev primer, 5′-CTTCCTTCCGGAGGAGTGC-3′. Analysis was carried out in triplicate.

*Cell Culture and Transient Expression*---HEK-293 (tsA-201) cells were cultured and transfected as described previously ([@ref4]). Untagged Ca~V~1.3α1 constructs were expressed together with β3 (or β2a) and α~2~δ 1 subunits ([@ref4]). In co-expression studies, GFP-labeled C-terminal Ca~V~1.3 fragments were used to ensure the presence of the corresponding C-terminal peptide in the cell recorded. Immunoblotting was performed as described previously ([@ref25]) using a generic anti-α1 sequence-directed antibody as described previously ([@ref4]). All constructs were expressed with the expected molecular mass.

*Electrophysiological Recordings*---Whole-cell patch clamp recordings in transiently transfected HEK-293 (tsA-201) cells were performed 2--3 days after transfection using either 15 m[m]{.smallcaps} Ba^2+^ or Ca^2+^ as charge carrier as described in Ref. [@ref4]. Recording solutions were composed as follows (in m[m]{.smallcaps}): intracellular solution, 135 CsCl, 10 Cs-EGTA, 1 MgCl~2~ adjusted to pH 7.4 with CsOH (311 mos[m]{.smallcaps}); bath solution, 15 BaCl~2~, 10 HEPES, 150 choline-Cl, and 1 MgCl~2~, adjusted to pH 7.4 with CsOH (358 mos[m]{.smallcaps}). Transfected cells were visualized by co-expression of GFP or GFP- or YFP-labeled constructs co-expressed with the channel complex as indicated. Current-voltage (*I-V*) relationships were obtained by holding cells at a potential of --90 mV before applying 50-ms or 300-ms pulses to various test potentials. *I-V* curves were fitted to the equation *I* = *G*~max~(*V* -- *V*~rev~)/{1 + exp((*V* -- *V*~0.5act~)/*k*)}, where *V*~rev~ is the extrapolated reversal potential; *V* is the test potential; *I* is the peak current amplitude; *G*~max~ is the maximum slope conductance; *V*~0.5,act~ is the half-maximal activation voltage; and *k* is the slope factor. Percentage of inactivation was determined at specified time points during depolarizing pulses from a holding potential of --90 mV to the peak current potential (*V*~max~) of the *I--V* relation of the individual cell. The voltage dependence of inactivation was assessed by application of a 20-ms test pulse to *V*~max~ before and after holding cells at various conditioning test potentials for 5 s. Steady-state inactivation curves were analyzed using the Boltzmann relationship *I* = *I~SS~* + (1 -- *I~SS~*)/(1 + exp(*V* -- *V*~0.5,inact~/*k*~inact~)), where *I* is the peak current amplitude; *I~SS~* is the noninactivating fraction; *V* is the membrane potential; *V*~0.5,inact~ is the half-inactivation potential; and *k*~inact~ is the slope factor. To investigate Ca~V~1.3~42~ and Ca~V~1.3~42A~ gating properties, head-to-head analysis was performed time-independently by two investigators. Experiments showing currents bigger than 3 nA were prospectively excluded from analysis of activation and inactivation parameters to guarantee high quality voltage clamp. CDI was quantified as the current remaining at the end of 250-ms depolarizations to different test potentials, expressed as fraction of peak current amplitude (*r*~250~). Parameter *f* was defined as the difference between *r*~250~ values of *I*~Ba~ and *I*~Ca~ at +10 mV. CDI experiments were performed on different cells, but effects were the same when the charge carrier was switched from Ba^2+^ to Ca^2+^ on the same cell in representative experiments. All voltages were corrected for the liquid junction potential.

Confocal FRET Microscopy
------------------------

Confocal FRET microscopy was performed as described previously ([@ref15]). As negative controls, peptide *YFP*-EF-PreIQ-IQ-PCRD was co-expressed with CFP alone (CFP control), and probes *CFP*-C~158~ or *CFP*-C~116~ with YFP alone (YFP controls 1 and 2). Image analysis was accomplished using a self-made program integrated in MatLab 7 based on the FRET analysis algorithm proposed ([@ref26]). Interaction between fragments was considered when a significant difference to the CFP as well as the corresponding YFP control was observed. The local ratio between CFP and YFP might vary because of different local expression levels of the different protein constructs, which could affect calculation of FRET values. Therefore, analysis was limited to pixels with a CFP:YFP molar ratio between 1:10 and 10:1.

Statistical Analysis
--------------------

Data were analyzed using Clampfit® 9.0 (Molecular Devices, Union City, CA) and Microcal Origin® 5.0 (Northampton, MA). Significant difference between the two splice variants was assessed *a priori* by pairwise comparison before other truncation constructs to characterize the modulatory mechanism were made. Student\'s *t* test or Mann-Whitney test were used for comparison between two groups for parametric and nonparametric data, respectively. Statistical significance was determined using one-way ANOVA followed by Bonferroni post-test, except if stated otherwise. Statistical significance was set at *p* \< 0.05. All data are presented as mean ± S.E. for the indicated number of experiments.

RESULTS
=======

*Ca~V~1.3 C-terminal Modulator Affects Voltage-dependent Channel Activity*---To test for the presence of a C-terminal modulator (CTM), we employed two previously described naturally occurring Ca~V~1.3 α1 subunit splice variants, Ca~V~1.3~42~ and Ca~V~1.3~42A~ (also termed Ca~V~1.3a and Ca~V~1.3b, respectively ([@ref5], [@ref27], [@ref28])), which differ with respect to the length of their C termini, as illustrated in [Fig. 1*a*](#fig1){ref-type="fig"}. Similar to the Ca~V~1.4 truncation mutant K1591*X* ([@ref15]), Ca~V~1.3~42A~ terminates shortly after the IQ motif and lacks most of a homologous region (termed PCRD) previously found to participate in the binding of distal C-terminal sequences in Ca~V~1.2 ([@ref17]). Wild-type long and short Ca~V~1.3 α1 subunits were expressed in HEK-293 cells together with β3 (or β2a) and α2δ 1. β3 subunits were selected because we have previously shown that they form a large fraction of dihydropyridine-sensitive LTCCs in the brain ([@ref29]). Both α1 subunits migrated with the expected molecular mass in Western blots of HEK-293 cell preparations ([Fig. 1*b*](#fig1){ref-type="fig"}).

FIGURE 1.**C-terminal splice variants Ca~V~1.3~42~ and Ca~V~1.3~42A~.** *a,* alternative usage of exon 42 results in either full-length (exon 42, *black*) or C-terminally truncated (exon 42A, *gray*) Ca~V~1.3 channels. *Arrows* indicate the approximate position of forward (*fwd*) and reverse (*rev*) PCR primers used in [Fig. 8](#fig8){ref-type="fig"}. *b,* immunoblot of both splice variants expressed together with β3 and α2δ1 subunits in HEK-293 cells, as described under "Experimental Procedures." Mock-transfected cells (*mock*) were used to show specificity of immunoreactivity. One representative experiment out of four is shown.

FIGURE 2.**Activation and steady-state inactivation properties of Ca~V~1.3~42~ compared with Ca~V~1.3~42A~ channels.** *a,* normalized mean *I*-*V* curves of *I*~Ca~ for Ca~V~1.3~42~ (*black*) and Ca~V~1.3~42A~ (*gray*) channels. Activation parameters and statistics are given in [Table 1](#tbl1){ref-type="table"}. The *dotted line* describes the fit to a normalized *I-V* curve of *I*~Ca~ for Ca~V~1.2 in comparison: *V*~0.5,act~, 8.8 mV; *k*~act~, --11.0 mV. Cell, 111d_16. *b,* representative current traces for *I*~Ca~ (300-ms depolarization to indicated test potentials). Cells: Ca~V~1.3~42~, 196l_23; Ca~V~1.3~42A~, 196l_32. *c, V*~0.5,act~ for Ca~V~1.3~42A~ was independent from current density. *d,* exemplar ON-gating currents for Ca~V~1.3~42~ and Ca~V~1.3~42A~ with similar *I*~Ba~ amplitudes measured by depolarizing cells to *V*~rev~. One representative out of six experiments is shown. Cells: Ca~V~1.3~42~, 207l_34; Ca~V~1.3~42A~, 237k_26. *e,* steady-state inactivation curves for Ca~V~1.3~42~ and Ca~V~1.3~42A~. Activation curves were obtained from parameters in *a. Solid lines* are fits to the Boltzmann relationship (see "Experimental Procedures"). Statistics are given under "Results." *Error bars* reflect S.E.

We systematically investigated the biophysical properties of both *I*~Ca~ and *I*~Ba~ for Ca~V~1.3~42~ and Ca~V~1.3~42A~ as illustrated in Figs. [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"} and Tables [1](#tbl1){ref-type="table"}, [2](#tbl2){ref-type="table"}, [3](#tbl3){ref-type="table"}. The voltage dependence of *I*~Ca~ activation of Ca~V~1.3~42A~ was significantly shifted to hyperpolarizing potentials by about 10 mV (Ca~V~1.3~42~: *V*~0.5,act~ = --2.2 ± 0.6 mV, *n* = 14; Ca~V~1.3~42A~: *V*~0.5,act~ = --12.9 ± 0.8 mV, *n* = 15; *p* \< 0.001; see [Table 1](#tbl1){ref-type="table"}). This negative shift was because of the significant decrease in *k*~act~ (Ca~V~1.3~42~: --9.1 ± 0.2, *n* = 14; Ca~V~1.3~42A~: --6.9 ± 0.2, *n* = 15; *p* \< 0.001; see [Table 1](#tbl1){ref-type="table"}) without change in the activation threshold ([Fig. 2*a*](#fig2){ref-type="fig"}). Such changes were also observed for *I*~Ba~ ([Table 2](#tbl2){ref-type="table"}). The negative activation range persisted when subgroups of cells with different current amplitudes (0.1--0.6 *versus* 0.7--2.3 nA) were compared ([Fig. 2*c*](#fig2){ref-type="fig"}). It was not restricted to β3 subunit-containing channel complexes because it was also seen when the Ca~V~1.3 splice variants were co-expressed with β2a subunits (*V*~0.5,act~, *I*~Ca~, Ca~V~1.3~42~, *V*~0.5,act~, 0.06 ± 3.2 mV, *n* = 3, Ca~V~1.3~42A~, *V*~0.5,act~, --11.2 ± 1.7 mV~,~ *n* = 3; *I*~Ba~, Ca~V~1.3~42~, --12.5 ± 1.6 mV, *n* = 7, Ca~V~1.3~42A~, --22.7 ± 1.3 mV, *n* = 6). Mean current density of Ca~V~1.3~42A~ channels was ∼2.5-fold higher for *I*~Ca~ (Ca~V~1.3~42~, 21.0 ± 3.3 pA/pF, *n* = 14; Ca~V~1.3~42A~, 98.3 ± 31.8, *n* = 19, *p* \< 0.01, Mann-Whitney test). A similar increase was observed for *I*~Ba~ (not shown). Increased current density occurred without detectable changes in the expression density as observed in immunoblots ([Fig. 1*b*](#fig1){ref-type="fig"}*, n* = 4). Depolarization to the reversal potential (*V*~rev~) revealed a small ON-gating current which was always detectable for Ca~V~1.3~42~ channels but was absent (or much reduced) in Ca~V~1.3~42A~ currents ([Fig. 2*d*](#fig2){ref-type="fig"}). This further suggests that the larger current amplitude of Ca~V~1.3~42A~ channels was not because of an increased expression density of channels at the plasma membrane in line with the immunoblot analysis.

TABLE 1Biophysical ICa properties of CaV1.342 and CaV1.342A channels in comparison with different C-terminally truncated CaV1.3 channel constructsNumber of experiments is indicated in parentheses.**Construct*V*~0.5,act~*k*~act~*V*~max~Activation threshold*V*~rev~***mVmVmVmVmV*Ca~V~1.3~42~ (14)-2.2 ± 0.6[*a*](#tblfn1){ref-type="table-fn"}-9.1 ± 0.2[*a*](#tblfn1){ref-type="table-fn"}13.3 ± 0.6[*a*](#tblfn1){ref-type="table-fn"}-35.6 ± 0.769.8 ± 1.1Ca~V~1.3~42A~ (15)-12.9 ± 0.8[*b*](#tblfn2){ref-type="table-fn"}-6.9 ± 0.2[*b*](#tblfn2){ref-type="table-fn"}1.9 ± 0.9[*b*](#tblfn2){ref-type="table-fn"}-37.1 ± 0.865.7 ± 1.1Ca~V~1.3~ΔC158~ (9)-14.3 ± 0.4[*b*](#tblfn2){ref-type="table-fn"}-7.4 ± 0.2[*b*](#tblfn2){ref-type="table-fn"}0.7 ± 0.5[*b*](#tblfn2){ref-type="table-fn"}-38.9 ± 0.6[*c*](#tblfn3){ref-type="table-fn"}62.4 ± 1.3[*b*](#tblfn2){ref-type="table-fn"}Ca~V~1.3~ΔC116~ (10)-12.0 ± 0.7[*b*](#tblfn2){ref-type="table-fn"}-7.7 ± 0.3[*d*](#tblfn4){ref-type="table-fn"}3.0 ± 0.8[*b*](#tblfn2){ref-type="table-fn"}-38.4 ± 0.561.4 ± 1.1[*b*](#tblfn2){ref-type="table-fn"}Ca~V~1.3~ΔC76~ (12)-14.6 ± 0.9[*b*](#tblfn2){ref-type="table-fn"}-7.0 ± 0.3[*b*](#tblfn2){ref-type="table-fn"}0.8 ± 1.2[*b*](#tblfn2){ref-type="table-fn"}-38.1 ± 0.463.5 ± 1.3[*d*](#tblfn4){ref-type="table-fn"}Ca~V~1.3~ΔC473~ (9)-12.8 ± 1.4[*b*](#tblfn2){ref-type="table-fn"}-7.3 ± 0.4[*b*](#tblfn2){ref-type="table-fn"}2.1 ± 1.7[*b*](#tblfn2){ref-type="table-fn"}-37.1 ± 1.164.7 ± 1.3Ca~V~1.3~42A~ + C~158~ (7)-12.6 ± 1.5[*b*](#tblfn2){ref-type="table-fn"}-7.6 ± 0.3[*d*](#tblfn4){ref-type="table-fn"}2.8 ± 1.5[*b*](#tblfn2){ref-type="table-fn"}-38.9 ± 0.763.6 ± 2.2[*c*](#tblfn3){ref-type="table-fn"}Ca~V~1.3~ΔC158~ + C~158~ (8)-0.8 ± 1.4[*a*](#tblfn1){ref-type="table-fn"}-9.7 ± 0.4[*a*](#tblfn1){ref-type="table-fn"}13.9 ± 1.2[*a*](#tblfn1){ref-type="table-fn"}-36.5 ± 0.967.5 ± 1.2Ca~V~1.3~ΔC116~ + C~116~ (7)-4.2 ± 0.7[*a*](#tblfn1){ref-type="table-fn"}-9.1 ± 0.4[*a*](#tblfn1){ref-type="table-fn"}10.0 ± 0.6[*a*](#tblfn1){ref-type="table-fn"}-38.2 ± 0.961.5 ± 1.3[*b*](#tblfn2){ref-type="table-fn"}Ca~V~1.3~ΔC76~ + C~76~ (11)-13.8 ± 0.9[*b*](#tblfn2){ref-type="table-fn"}-7.1 ± 0.2[*b*](#tblfn2){ref-type="table-fn"}1.5 ± 1.2[*b*](#tblfn2){ref-type="table-fn"}-37.2 ± 0.761.5 ± 1.3[*b*](#tblfn2){ref-type="table-fn"}Ca~V~1.3~ΔC473~ + C~116~ (9)-3.1 ± 1.4[*a*](#tblfn1){ref-type="table-fn"}-9.1 ± 0.3[*a*](#tblfn1){ref-type="table-fn"}11.7 ± 1.2[*a*](#tblfn1){ref-type="table-fn"}-35.7 ± 0.365.4 ± 0.9[^1][^2][^3][^4]

TABLE 2Biophysical IBa properties of CaV1.342 and CaV1.342A channels in comparison with different C-terminally truncated CaV1.3 channel constructsNumber of experiments is indicated in parentheses.**Construct*V*~0.5,act~*k*~act~*V*~max~Activation threshold*V*~rev~***mVmVmVmVmV*Ca~V~1.3~42~ (18)-11.8 ± 0.9[*a*](#tblfn5){ref-type="table-fn"}-7.8 ± 0.2[*b*](#tblfn6){ref-type="table-fn"}3.4 ± 0.9[*b*](#tblfn6){ref-type="table-fn"}-39.9 ± 0.7[*b*](#tblfn6){ref-type="table-fn"}58.2 ± 0.9[*a*](#tblfn5){ref-type="table-fn"}Ca~V~1.3~42A~ (12)-20.2 ± 1.0[*c*](#tblfn7){ref-type="table-fn"}-6.6 ± 0.3[*d*](#tblfn8){ref-type="table-fn"}-6.6 ± 1.2[*d*](#tblfn8){ref-type="table-fn"}-43.3 ± 0.6[*d*](#tblfn8){ref-type="table-fn"}50.7 ± 1.6[*c*](#tblfn7){ref-type="table-fn"}Ca~V~1.3~ΔC158~ (12)-20.9 ± 1.2[*c*](#tblfn7){ref-type="table-fn"}-5.7 ± 0.3[*c*](#tblfn7){ref-type="table-fn"}-8.4 ± 1.5[*c*](#tblfn7){ref-type="table-fn"}-41.7 ± 0.546.4 ± 1.6[*c*](#tblfn7){ref-type="table-fn"}Ca~V~1.3~ΔC116~ (9)-22.9 ± 0.6[*c*](#tblfn7){ref-type="table-fn"}-5.9 ± 0.2[*c*](#tblfn7){ref-type="table-fn"}-10.3 ± 0.8[*c*](#tblfn7){ref-type="table-fn"}-43.7 ± 0.5[*d*](#tblfn8){ref-type="table-fn"}44.2 ± 1.2[*c*](#tblfn7){ref-type="table-fn"}^,^[*e*](#tblfn9){ref-type="table-fn"}Ca~V~1.3~ΔC76~ (10)-22.8 ± 0.5[*c*](#tblfn7){ref-type="table-fn"}-5.5 ± 0.1[*c*](#tblfn7){ref-type="table-fn"}-9.9 ± 0.6[*c*](#tblfn7){ref-type="table-fn"}-41.9 ± 0.448.1 ± 0.8[*c*](#tblfn7){ref-type="table-fn"}Ca~V~1.3~ΔC473~ (6)-22.2 ± 0.9[*c*](#tblfn7){ref-type="table-fn"}-5.9 ± 0.1[*c*](#tblfn7){ref-type="table-fn"}-8.9 ± 1.0[*d*](#tblfn8){ref-type="table-fn"}-42.2 ± 0.749.1 ± 0.7[*c*](#tblfn7){ref-type="table-fn"}Ca~V~1.3~42A~ + C~158~ (7)-22.2 ± 1.2[*c*](#tblfn7){ref-type="table-fn"}-6.1 ± 0.4[*c*](#tblfn7){ref-type="table-fn"}-8.8 ± 1.5[*c*](#tblfn7){ref-type="table-fn"}-44.1 ± 0.9[*c*](#tblfn7){ref-type="table-fn"}48.8 ± 1.1[*c*](#tblfn7){ref-type="table-fn"}Ca~V~1.3~ΔC158~ + C~158~ (11)-10.3 ± 0.9[*a*](#tblfn5){ref-type="table-fn"}-8.2 ± 0.2[*a*](#tblfn5){ref-type="table-fn"}3.6 ± 0.8[*a*](#tblfn5){ref-type="table-fn"}-40.1 ± 0.7[*e*](#tblfn9){ref-type="table-fn"}56.4 ± 1.2[*e*](#tblfn9){ref-type="table-fn"}Ca~V~1.3~ΔC116~ + C~116~ (7)-13.3 ± 1.2[*a*](#tblfn5){ref-type="table-fn"}-7.8 ± 0.2[*e*](#tblfn9){ref-type="table-fn"}1.2 ± 1.2-41.2 ± 0.954.9 ± 1.3Ca~V~1.3~ΔC76~ + C~76~ (9)-22.1 ± 0.8[*c*](#tblfn7){ref-type="table-fn"}-5.9 ± 0.2[*c*](#tblfn7){ref-type="table-fn"}-7.5 ± 1.3[*c*](#tblfn7){ref-type="table-fn"}-42.6 ± 0.649.2 ± 1.2[*c*](#tblfn7){ref-type="table-fn"}Ca~V~1.3~ΔC473~ + C~116~ (11)-15.6 ± 1.2[*e*](#tblfn9){ref-type="table-fn"}-7.6 ± 0.1[*e*](#tblfn9){ref-type="table-fn"}-1.7 ± 1.1[*d*](#tblfn8){ref-type="table-fn"}^,^[*e*](#tblfn9){ref-type="table-fn"}-42.9 ± 0.8[*d*](#tblfn8){ref-type="table-fn"}50.8 ± 0.8[*c*](#tblfn7){ref-type="table-fn"}[^5][^6][^7][^8][^9]

TABLE 3ICa and IBa inactivation and CDI properties of CaV1.342 and CaV1.342A channels in comparison with different C-terminally truncated CaV1.3 channel constructsNumber of experiments is indicated in parentheses.**Construct*I*~Ca~ inactivation during 30 ms*I*~Ba~ inactivation during 250 ms*f* value, *n* = 6-11**%%Ca~V~1.3~42~27.5 ± 1.9[*a*](#tblfn10){ref-type="table-fn"} (16)39.8 ± 1.6[*a*](#tblfn10){ref-type="table-fn"} (8)0.25 ± 0.11Ca~V~1.3~42A~73.6 ± 1.9[*b*](#tblfn11){ref-type="table-fn"} (19)21.1 ± 3.8[*b*](#tblfn11){ref-type="table-fn"} (14)0.60 ± 0.07Ca~V~1.3~ΔC158~70.4 ± 2.2[*b*](#tblfn11){ref-type="table-fn"} (8)16.9 ± 3.5[*b*](#tblfn11){ref-type="table-fn"} (7)0.60 ± 0.05Ca~V~1.3~ΔC116~72.6 ± 1.5[*b*](#tblfn11){ref-type="table-fn"} (8)8.5 ± 1.9[*b*](#tblfn11){ref-type="table-fn"},[*c*](#tblfn12){ref-type="table-fn"} (9)0.66 ± 0.05Ca~V~1.3~ΔC76~74.3 ± 1.8[*b*](#tblfn11){ref-type="table-fn"} (9)14.9 ± 1.9[*b*](#tblfn11){ref-type="table-fn"} (11)0.72 ± 0.04Ca~V~1.3~ΔC473~71.7 ± 1.3[*b*](#tblfn11){ref-type="table-fn"} (7)15.9 ± 2.9[*b*](#tblfn11){ref-type="table-fn"} (8)0.67 ± 0.06Ca~V~1.3~42A~ + C~158~67.1 ± 2.5[*b*](#tblfn11){ref-type="table-fn"} (6)10.3 ± 1.3[*b*](#tblfn11){ref-type="table-fn"} (5)0.71 ± 0.06Ca~V~1.3~ΔC158~ + C~158~23.5 ± 1.9[*a*](#tblfn10){ref-type="table-fn"} (8)30.2 ± 2.5 (12)0.20 ± 0.08Ca~V~1.3~ΔC116~ + C~116~34.8 ± 2.0[*c*](#tblfn12){ref-type="table-fn"} (7)35.3 ± 2.7[*c*](#tblfn12){ref-type="table-fn"} (7)0.29 ± 0.05Ca~V~1.3~ΔC76~ + C~76~67.2 ± 2.4[*b*](#tblfn11){ref-type="table-fn"} (7)18.5 ± 2.6[*b*](#tblfn11){ref-type="table-fn"} (9)0.56 ± 0.06Ca~V~1.3~ΔC473~ + C~116~32.2 ± 4.6[*a*](#tblfn10){ref-type="table-fn"} (8)35.4 ± 1.9[*c*](#tblfn12){ref-type="table-fn"} (9)0.27 ± 0.05[^10][^11][^12]

The short C terminus also resulted in a slight decrease of *V*~rev~ (with a larger and statistically significantly difference for *I*~Ba~; see Tables [1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). The half-maximal voltage of steady-state inactivation (*V*~0.5,act~) induced by 10-s conditioning pulses ([Fig. 2*e*](#fig2){ref-type="fig"}) for the physiological charge carrier was also significantly shifted toward more negative voltages in Ca~V~1.3~42A~ channels (Ca~V~1.3~42~: --31.6 ± 1.1 mV, *n* = 5; Ca~V~1.3~42A~: --38.8 ± 1.6 mV, *n* = 4, *p* = 0.007, Student\'s *t* test). A significant difference in the slope factor (*k*~inact~, Ca~V~1.3~42~: --6.4 ± 0.3 mV, *n* = 5; Ca~V~1.3~42A~: --4.9 ± 0.5 mV, *n* = 4, *p* = 0.03, Student\'s *t* test) was also observed. Theses changes in the voltage dependence of steady-state activation and inactivation resulted in a shift of the window current toward more hyperpolarizing voltages for Ca~V~1.3~42A~ ([Fig. 2*e*](#fig2){ref-type="fig"}). Our data demonstrate that the structural divergence within the C termini of these Ca~V~1.3 splice variants causes pronounced changes in channel gating suggesting the existence of a CTM in Ca~V~1.3 LTCCs that controls their activity at negative voltages.

*Ca~V~1.3 C Terminus Modulates Ca^2^*^+^*-dependent Inactivation Properties*---As already obvious from the representative current traces in [Fig. 2*b*](#fig2){ref-type="fig"}, Ca~V~1.3~42A~ channels inactivate faster during depolarization to different test potentials than Ca~V~1.3~42~ channels. This is also evident from a detailed comparison of *I*~Ca~ inactivation during 10-s pulses to the maximum of the *I-V* curve (*V*~max~) ([Fig. 3, *a* and *b*](#fig3){ref-type="fig"}; [Table 3](#tbl3){ref-type="table"}). The difference was most pronounced during the first 30 ms (% inactivation: Ca~V~1.3~42~, 27.5 ± 1.9, *n* = 16; Ca~V~1.3~42A~, 73.6 ± 1.9, *n* = 19, *p* \< 0.001; [Fig. 3, *a, inset*, and *b*](#fig3){ref-type="fig"}, and [Table 3](#tbl3){ref-type="table"}). Inactivation included an initial fast component followed by a slow component in both isoforms. Inactivation was not complete even during 10 s (Ca~V~1.3~42~, 96.9 ± 0.7%, *n* = 14; Ca~V~1.3~42A~, 98.1 ± 0.3%, *n* = 17; one sample *t* test, compared with 100%: *p* = 0.0006 for Ca~V~1.3~42~ and *p* = 0.0001 for Ca~V~1.3~42A~) suggesting that some Ca^2+^ influx through Ca~V~1.3 channels may persist even during extended periods of strong depolarization. Faster *I*~Ca~ inactivation of Ca~V~1.3~42A~ was also seen at physiologically more relevant potentials, as indicated by a significant decrease in integrated *I*~Ca~ during 300-ms test pulses ([Fig. 3*c*](#fig3){ref-type="fig"}). Note that voltage dependence of activation and inactivation is shifted by ∼15 mV to more positive voltages under our recording conditions ([@ref5]). Therefore, --20 mV corresponds to about --35 mV at physiological Ca^2+^ concentrations.

FIGURE 3.**Inactivation properties of Ca~V~1.3~42~ and Ca~V~1.3~42A~ channel-mediated currents.** *a,* representative current traces of Ca~V~1.3~42~ (*black*) and Ca~V~1.3~42A~ (*gray*) *I*~Ca~ evoked by a 10-s depolarization to *V*~max~. The *inset* illustrates inactivation during initial 30 ms. Cells: Ca~V~1.3~42~, 316h_51; Ca~V~1.3~42A~, 187g_46. *b,* percent *I*~Ca~ inactivation during 0.03-, 0.25-, 1-, and 5-s test pulses to *V*~max~. \*\*\*, *p* ≤ 0.001, Student\'s *t* test. *c,* normalized representative *I*~Ca~ traces at physiologically relevant potentials (--20 mV; corresponding to ∼--35 mV at physiological Ca^2+^ concentrations; see "Results"). Cells: Ca~V~1.3~42~, 196l_23; Ca~V~1.3~42A~, 187g_17. Integrated current corresponding to the area under normalized *I*~Ca~ during a 300-ms pulse is shown. Statistically significant difference: \*\*\*, *p* ≤ 0.001, Unpaired *t* test. *d,* percent *I*~Ba~ inactivation during 0.03-, 0.25-, 1-, and 5-s test pulses to *V*~max~. \*, *p* \< 0.05; \*\*, *p* \< 0.01, Student *t* test. *e,* voltage dependence of CDI for Ca~V~1.3~42~ (*left*) and Ca~V~1.3~42A~ (*right*): *r*~250~ corresponds to the fraction of *I*~Ca~ or *I*~Ba~ remaining after 250 ms; *f* is the difference between *r*~250~ values at +10 mV (for statistics see "Results" and [Table 3](#tbl3){ref-type="table"}). Number of experiments is given in parentheses. *Error bars* reflect S.E.

The faster inactivation of Ca~V~1.3~42A~ could be due to faster voltage-dependent inactivation, faster CDI, or both. To address this question, we also quantified Ca~V~1.3-mediated *I*~Ba~ of both splice variants. Interestingly, mean *I*~Ba~ inactivation was even slower for Ca~V~1.3~42A~ channels ([Fig. 3*d*](#fig3){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"}). This difference was because of a pronounced slowing of inactivation in 50% of the cells (% inactivation of Ca~V~1.3~42A~ during 250 ms, 8.6 ± 1.2%, *n* = 7, in this subset). We have previously observed a similar slowing of inactivation of *I*~Ba~ in truncated Ca~V~1.4 channels ([@ref15]).

From these data we conclude that the faster inactivation of *I*~Ca~ observed for Ca~V~1.3~42A~ must be due to more pronounced CDI. As a quantitative measure of CDI, we analyzed the fraction of *I*~Ca~ through Ca~V~1.3 channels remaining after a 250-ms depolarization (*r*~250~) in a wide voltage range ([Fig. 3*e*](#fig3){ref-type="fig"}). A typical U-shaped dependence on test voltage was observed for both splice variants, but it was more pronounced for Ca~V~1.3~42A~ channels (*f* = 0.60 ± 0.07 *versus* 0.25 ± 0.11 at 10 mV for Ca~V~1.3~42~ channels). In agreement with a previous report ([@ref13]), Ca~V~1.3 CDI was CaM-mediated. *I*~Ca~ inactivation of Ca~V~1.3~42A~ channels was dramatically slowed by co-expression of YFP-labeled dominant-negative CaM (CaM~1234~) (*r*~250~ at *V*~max~:Ca~V~1.3~42A~ + CaM~1234~, 0.76 ± 0.061%, *n* = 5, *p* \< 0.0001, Student\'s *t* test *versus* Ca~V~1.3~42A~) thus approaching *r*~250~ values for *I*~Ba~ (for comparison see [Fig. 3*e*](#fig3){ref-type="fig"}). CaM~1234~ did not affect the hyperpolarizing shift of the *I*~Ca~ activation (*V*~0.5,act~:Ca~V~1.3~42A~ + CaM~1234~: --16.3 ± 0.5 mV, *n* = 8) suggesting that the shift in activation voltage occurs independent of CaM as also shown previously for Ca~V~1.4 ([@ref15]). Taken together, these data provide unequivocal evidence that the CTM in Ca~V~1.3 channels not only modulates its activity range but also moderates CDI.

*Ca~V~1.3 CTM Lies within the Most Distal C-terminal Domain Highly Conserved in LTCCs*---To further strengthen this hypothesis and pinpoint important structural domains, we tested if different C-terminal truncations exhibit similar gating effects. In accordance to the C-terminal peptide C~122~ important for Ca~V~1.4 channel modulation ([@ref15]), we deleted the corresponding distal 158 amino acids of Ca~V~1.3~42~. The resulting Ca~V~1.3~ΔC158~ channels exhibited *I*~Ca~ and *I*~Ba~ activation properties comparable with Ca~V~1.3~42A~ (Tables [1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). For *I*~Ca~, *k*~act~ significantly decreased (Ca~V~1.3~ΔC158~: --7.4 ± 0.2, *n* = 9; *p* \< 0.001; [Table 1](#tbl1){ref-type="table"}), and *V*~0.5,act~ (Ca~V~1.3~ΔC158~: --14.3 ± 0.4 mV, *n* = 9, *p* \< 0.001; [Table 1](#tbl1){ref-type="table"}) shifted to more hyperpolarized voltages. Like in Ca~V~1.3~42A~, *I*~Ca~ inactivation was faster, and CDI was more pronounced, and *I*~Ba~ was slowed (for all data and statistics see Tables [1](#tbl1){ref-type="table"}, [2](#tbl2){ref-type="table"}, [3](#tbl3){ref-type="table"}).

To prove the modulatory role of the last 158 amino acid residues, we tested the capability of this C-terminal fragment to restore the gating changes induced by the truncation. Therefore, GFP-fused peptide (GFP-C~158~) was expressed together with the respective truncated channel. GFP-C~158~ reverted the gating changes observed in Ca~V~1.3~ΔC158~ channels to values similar to Ca~V~1.3~42~; the hyperpolarizing shift of the *I*~Ca~ activation curve was reversed (*V*~0.5,~ ~act~:Ca~V~1.3~ΔC158~ + GFP-C~158~, --0.8 ± 1.4 mV *n* = 8, *p* = 0.3 *versus* Ca~V~1.3~42~; see [Table 1](#tbl1){ref-type="table"}); *I*~Ca~ inactivation was slowed (during 30 ms: Ca~V~1.3~ΔC158~ + GFP-C~158~; 23.5 ± 1.9%, *n* = 8, *p* = 0.2 *versus* Ca~V~1.3~42~; see [Table 3](#tbl3){ref-type="table"}), and CDI was less pronounced as indicated by the decrease of the *f* value (at 10 mV, Ca~V~1.3~ΔC158~ + GFP-C~158~, 0.2 ± 0.08, *n* = 6--8; see [Table 3](#tbl3){ref-type="table"}). Peptide-induced reversal of activation and inactivation parameters was also observed in *I*~Ba~ ([Table 2](#tbl2){ref-type="table"}).

FIGURE 4.**Gating properties of Ca~V~1.3~ΔC116~ channels and effect of the distal CTM peptide C~116~.** Data for Ca~V~1.3~42~ were taken from [Fig. 2. *a,*](#fig2){ref-type="fig"} representative normalized *I-V* curves for *I*~Ca~. Activation parameters were as follows (in mV): Ca~V~1.3~42~: *V*~0.5,act,~ --4.2, and *k*~act~, --8.6; Ca~V~1.3~ΔC116~: *V*~0.5,act~: --12.8, and *k*~act~, --7.7; Ca~V~1.3~ΔC116~+GFP-C~116~: *V*~0.5,act~, --4.7, and *k*~act~, --8.8; Cells: 196l_23, 27g_57, and 27g_91, respectively. *b,* representative current traces of *I*~Ca~ evoked by a depolarization to *V*~max~. Cells: Ca~V~1.3~ΔC116~, 27g_27; Ca~V~1.3~ΔC116~+GFP-C~116~, 197f_26. *c,* percent *I*~Ca~ inactivation during test pulses to *V*~max~: \*\*, *p* \< 0.01; \*\*\*, *p* \< 0.001, compared with Ca~V~1.3~42~ (*black*); +, *p* \< 0.05; +++, *p* \< 0.001, comparison of Ca~V~1.3~ΔC116~ + GFP-C~116~ (*white*) with Ca~V~1.3~ΔC116~ (*gray*) alone (one-way ANOVA followed by Bonferroni post-test). Number of experiments is given in *parentheses. Error bars* reflect S.E. *d* and *e,* representative *I*~Ca~ traces for Ca~V~1.3~ΔC116~ (*d*) and Ca~V~1.3~ΔC116~+GFP-C~116~ (*e*). Cells: 27g_67 and 27g_91, respectively. For comparison to Ca~V~1.3~42~ see [Fig. 2](#fig2){ref-type="fig"}.

To further restrict the protein domain important for CTM activity, we introduced additional truncations in the distal C terminus (Figs. [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}). Deletion of the last 76 (Ca~V~1.3~ΔC76~) amino acids induced the same gating effects as described for Ca~V~1.3~ΔC158~. However, Ca~V~1.3~ΔC76~ channel activity was not reverted to Ca~V~1.3~42~-like behavior by co-expression of peptide GFP-C~76~ (for data and statistics see Tables [1](#tbl1){ref-type="table"}, [2](#tbl2){ref-type="table"}, [3](#tbl3){ref-type="table"}). This could not be explained by a lack of GFP-C~76~ expression because full-length expression of this peptide was confirmed in Western blot experiments where the peptide expressed at comparable levels to GFP-C~158~ (*n* = 3, not illustrated). Our data therefore suggest that the last 76 amino acids are required for the formation of CTM activity but cannot functionally recombine with its truncated counterpart to form a modulatory structure. Sequence alignment with other LTCCs ([Fig. 6](#fig6){ref-type="fig"}) revealed that truncation ΔC76 cuts in half the most distal highly conserved domain. This may prevent recombination to a functional domain upon co-expression. Hence, we generated Ca~V~1.3~ΔC116~ in which the conserved region was fully removed and subsequently co-expressed as a single peptide. As shown in [Fig. 4](#fig4){ref-type="fig"} and Tables [1](#tbl1){ref-type="table"}, [2](#tbl2){ref-type="table"}, [3](#tbl3){ref-type="table"}, Ca~V~1.3~ΔC116~ again exhibited functional *I*~Ca~ and *I*~Ba~ properties similar to Ca~V~1.3~42A~. However, unlike in Ca~V~1.3~ΔC76~, the gating properties were reversed to those of Ca~V~1.3~42~ after co-expression of the GFP-C~116~ peptide ([Fig. 4](#fig4){ref-type="fig"} and Tables [1](#tbl1){ref-type="table"}, [2](#tbl2){ref-type="table"}, [3](#tbl3){ref-type="table"}). Co-expression of the corresponding distal peptides not only reversed activation parameters and CDI but also significantly decreased mean *I*~Ca~ density by 53--63% (*p* \< 0.05, *n* = 7--11). A similar trend was also seen for *I*~Ba~ (41--67%, *n* = 7--11). These data implicate that Ca~V~1.3 α1 subunits contain critical structural elements required for CTM function within the last 76 amino acids and that the last 116 residues perform CTM activity when co-expressed in HEK-293 cells.

*Intramolecular Protein-Protein Interaction Regulates Ca~V~1.3 Channel Gating*---We ([@ref15]) and others ([@ref16]) showed that in Ca~V~1.4 α1 subunits the distal CTM interacts with a more proximal domain containing the EF-hand, pre-IQ-, and IQ-motif. If such a mechanism also holds true for Ca~V~1.3 channels, CTM-containing peptides should also modulate Ca~V~1.3~42A~ (containing EF-PreIQ-IQ). Interestingly, co-expression of GFP-C~158~ neither reversed the Ca~V~1.3~42A~-induced hyperpolarizing shift of the activation range of *I*~Ca~ (Ca~V~1.3~42A~ + GFP-C~158~: *V*~0.5,act~ = --12.6 ± 1.5 mV, *n* = 7; *p* \< 0.001; see [Fig. 5*a*](#fig5){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}) and *I*~Ba~ ([Table 2](#tbl2){ref-type="table"}) nor the voltage-dependent inactivation and CDI ([Fig. 5, *b* and *c*](#fig5){ref-type="fig"}; [Table 3](#tbl3){ref-type="table"}). This prompted us to extend the Ca~V~1.3 α1 subunit C terminus to residue 1664 thereby including a highly conserved domain downstream of the IQ-motif that is missing in Ca~V~1.3~42A~ and also contains the so-called PCRD domain previously identified as binding partner for C-terminal peptides in Ca~V~1.2 channels ([Fig. 6](#fig6){ref-type="fig"}) ([@ref17]). As expected, the resulting Ca~V~1.3~ΔC473~ channels showed Ca~V~1.3~42A~-like gating (Tables [1](#tbl1){ref-type="table"}, [2](#tbl2){ref-type="table"}, [3](#tbl3){ref-type="table"}) but, in contrast to Ca~V~1.3~42A~, co-expression of GFP-C~116~ restored CDI ([Fig. 5, *h* and *i*](#fig5){ref-type="fig"}; [Table 3](#tbl3){ref-type="table"}) and the activation and inactivation parameters for *I*~Ca~ ([Fig. 5, *d--f* and *h* and *i*](#fig5){ref-type="fig"}; and Tables [1](#tbl1){ref-type="table"} and [3](#tbl3){ref-type="table"}) and *I*~Ba~ (Tables [2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}) close to Ca~V~1.3~42~ values. These data provide functional evidence for an important role of proximal residues 1626--1664 and the distal 116 amino acids for CTM function.

To provide further evidence for this mechanism, we measured FRET between different YFP-labeled C-terminal fragments and CFP-labeled C~158~ (CFP-C~158~) as well as CFP-labeled C~116~ (CFP-C~116~) ([Fig. 7](#fig7){ref-type="fig"}). The construct corresponding to the C-terminal fragment of Ca~V~1.3~42A~ (YFP-EF-PreIQ-IQ) did not show significant FRET with the CFP-C~158~ probe (legend to [Fig. 7](#fig7){ref-type="fig"}). By extending the Ca~V~1.3 YFP-EF-preIQ-IQ bait to residue 1664 yielding YFP-EF-preIQ-IQ-PCRD, a strong and significant FRET signal was measured with CFP-C~158~ as well CFP-C~116~ ([Fig. 7](#fig7){ref-type="fig"}), which is in excellent agreement with our electrophysiological data. Accordingly, no FRET was observed when CFP-C~76~ peptide was used as a probe (not shown). For Ca~V~1.2 channels, interaction between a pair of arginine residues in the PCRD and a set of negatively charged residues in the distal C-terminal region (DCRD) was predicted ([Fig. 6](#fig6){ref-type="fig"}) ([@ref17]). As shown in [Fig. 7](#fig7){ref-type="fig"}, mutating the two conserved arginines in the Ca~V~1.3 PCRD to glutamine (EF-preIQ-IQ-PCRD*^RRQQ^* containing R1640Q and R1641Q) still supported a significant FRET signal when co-expressed with CFP-C~116~. Using probe CFP-C~116~^*DEQQ*^, where the two negative charges in DCRD conserved in Ca~V~1.3 were neutralized (D2073Q and E2076Q), significant FRET was eliminated for both EF-preIQ-IQ-PCRD and EF-preIQ-IQ-PCRD*^RRQQ^*. Therefore, neutralization of the two positive charges of the PCRD arginines is not sufficient to prevent the binding interaction suggesting that other binding determinants exist in the conserved domain between residues 1626 and 1664. Our data indicate an essential role of the two negative charges in the Ca~V~1.3~42~ DCRD region, similar to Ca~V~1.2.

FIGURE 5.**Ca~V~1.3~ΔC473~ channel properties in absence and presence of distal CTM peptide C~116~.** Data for Ca~V~1.3~42~ (*black*) and Ca~V~1.3~42A~ (*gray*) were taken from Figs. [2](#fig2){ref-type="fig"} and [4](#fig4){ref-type="fig"}. *a,* representative normalized *I-V* curves for *I*~Ca~. Activation parameters (in mV): Ca~V~1.3~42A~: *V*~0.5,act~, --14.3, and *k*~act~, --6.8; Ca~V~1.3~42A~ + GFP-C~158~: *V*~0.5,act~, --13.5 and *k*~act~, --7.2; Cells: 196l_32 and 217c_3, respectively. *b,* representative current traces of *I*~Ca~ evoked a 10-s depolarization to *V*~max~. Cells: Ca~V~1.3~42A~ + GFP-C~158~, 227k_19; Ca~V~1.3~42~, 316h_51; Ca~V~1.3~42A~, 187g_46. *c,* percent *I*~Ca~ inactivation during test pulses to *V*~max~:\*, *p* \< 0.05; \*\*\*, *p* \< 0.001 compared with Ca~V~1.3~42~; ++, *p* \< 0.01; +++, *p* \< 0.001, comparison of Ca~V~1.3~42A~ + GFP-C~158~ with Ca~V~1.3~42A~ alone. *d,* representative normalized *I-V* curves for *I*~Ca~. Activation parameters (in mV): Ca~V~1.3~ΔC473~: *V*~0.5,act~, --14.4, and *k*~act~, --7.1; Ca~V~1.3~ΔC473~ +GFP-C~116~: *V*~0.5,act~, --2.4, and *k*~act~, --9.4; Cells: 177i_1 and 167j_24, respectively. *e,* same conditions as in *b.* Cells: Ca~V~1.3~ΔC473~, 247h_25; Ca~V~1.3~ΔC473~ +GFP-C~116~, 167j_14. *f,* percent *I*~Ca~ inactivation during test pulses to *V*~max~:\*, *p* \< 0.05; \*\*, *p* \< 0.01; \*\*\*, *p* \< 0.001 compared with Ca~V~1.3~42~; +, *p* \< 0.05; ++, *p* \< 0.01; +++, *p* \< 0.001, comparison of Ca~V~1.3~ΔC473~ + GFP-C~116~ with Ca~V~1.3~ΔC473~ alone. *g--i,* representative *I*~Ca~ traces for Ca~V~1.3~42A~ + GFP-C~158~ (*g*), Ca~V~1.3~ΔC473~ (*h*), and Ca~V~1.3~ΔC473~ + GFP-C~116~ (*i*) correspond to *I-V* curves in *a* and *d*. For comparison to Ca~V~1.3~42~ and Ca~V~1.3~42A~ see [Fig. 2](#fig2){ref-type="fig"}. For statistics: in *a* and *d,* Student\'s *t* test; *c* and *f,* one-way ANOVA followed by Bonferroni post-test. Number of experiments is given in *parentheses. Error bars* reflect S.E.

To address the question if the moderation of CDI by the CTM involves modulation of CaM interaction with its C-terminal interaction domains, we measured if the presence of the CTM can affect the constitutive binding of CaM at resting intracellular Ca^2+^ concentrations. We measured FRET between CFP-labeled calmodulin (CFP-CaM) and the fragments YFP-EF-preIQ-IQ (mimicking the short Ca~V~1.3~42A~), YFP-EF-preIQ-IQ-PCRD, and a peptide corresponding to the complete Ca~V~1.3 C terminus (YFP-Ca~V~1.3-C terminus), including the CTM (corresponding to the long Ca~V~1.3~42~). Whereas significant *N*~FRET~ (*p* \< 0.001 *versus* YFP-Ca~V~1.3-C terminus; one-way ANOVA, Bonferroni post-test) was measured for YFP-EF-preIQ-IQ (0.185 ± 0.009, *n* = 12) and YFP-EF-preIQ-IQ-PCRD (0.235 ± 0.007, *n* = 3), no significant *N*~FRET~ was obtained for YFP-Ca~V~1.3-C terminus (0.039 ± 0.017, *n* = 6, *p* = 0.07. one-sample *t* test, compared with 0). This is in excellent agreement with our previous findings in Ca~V~1.4 channels ([@ref15]) indicating that the Ca~V~1.3 CTM interferes with CaM coordination to the C terminus in intact cells. This also provides a plausible mechanism for explaining the moderation of CDI.

We also investigated whether the function of the CTM was prevented by alternative splicing of exon 44 in the post-IQ region of the C terminus ([Fig. 6](#fig6){ref-type="fig"}). Introduction of 9 amino acid corresponding to exon 44 into a full-length Ca~V~1.3 construct (Ca~V~1.3~42+44~) exhibited activation parameters similar to Ca~V~1.3~42~ (*I*~Ba~: *V*~0.5,~ ~act~ = --14.8 ± 1.2 mV, *k*~act~ = --9.3 ± 0.3 mV, *n* = 14; *I*~Ca~, *V*~0.5,~ ~act~ = --3.7 ± 1.02 mV, *k*~act~ = --10.6 ± 0.3 mV, *n* = 8) suggesting that CTM function was not prevented by alternative splicing of this exon.

*Ca~V~1.3~42~ and Ca~V~1.3~42A~ Are Both Expressed in Mouse and Human Tissues*---We employed PCR to determine whether both long (CTM-containing) and short (CTM-deficient) splice variants are expressed in mouse and human tissue. RT-PCR experiments identified both exon 42 and 42A mRNA in different mouse brain regions and the organ of Corti ([Fig. 8*a*](#fig8){ref-type="fig"}) as well as in human brain, heart, retina, and pancreas ([Fig. 8*b*](#fig8){ref-type="fig"}). Using quantitative real time PCR, we determined the relative abundance of these transcripts in mouse whole-brain as well as several brain sub-regions ([Fig. 8*c*](#fig8){ref-type="fig"}). Because exons 42 and 42A are used in a mutually exclusive manner, we calculated the relative amount of exon 42A as percentage of the sum of exon 42 and 42A containing mRNA molecules in samples from two to three independent RNA preparations. Although exon 42 was the predominant form in whole-brain and all sub-regions investigated, significant expression of exon 42A was also found. In whole-brain preparations, exon 42A was 11.0 ± 0.6% (*n* = 8) of the two mRNAs. Variable expression was found in brain sub-regions with the highest expression in cerebellum (17.1 ± 2.5%, *n* = 4) and the nucleus accumbens (13.3 ± 1.5%, *n* = 3) and the lowest in olfactory bulb (2.1 ± 0.2%, *n* = 3). These data suggest that the short Ca~V~1.3 splice variant can contribute significantly to overall Ca~V~1.3 activity. Notably, our experiments do not rule out the possibility of other short isoforms with gating properties similar to Ca~V~1.3~42A~. Therefore the contribution of short forms to overall Ca~V~1.3 expression is likely to be underestimated by our experiments.

FIGURE 6.**Sequence alignment of LTCC C termini.** A sequence alignment of neuronal human Ca~V~1.3 (GenBank™ accession number NM_000720), Ca~V~1.4 (GenBank™ accession number AJ224874), and Ca~V~1.2 (uniprot accession number Q13936) α1 subunits is shown. Sequence identity (*dark gray*), similarity (*light gray*) and gaps (--) are indicated. *PCRD*, proximal C-terminal regulatory domain; *DCRD*, distal C-terminal regulatory domain; CTM, *dotted line*. Position of Ca~V~1.3~42A~ and truncation mutants Ca~V~1.3~ΔC473~, Ca~V~1.3~ΔC158,~ Ca~V~1.3~ΔC116~, and Ca~V~1.3~ΔC76~ are indicated by *black arrows.* Position of exon 44 is given.

DISCUSSION
==========

Here we present functional evidence for a C-terminal automodulatory domain that controls voltage- and Ca^2+^-dependent gating properties of Ca~V~1.3 LTCCs. Such modulation has not been described for Ca~V~1.3 channels before. The absence of the CTM in the short splice variant Ca~V~1.3~42A~ provides functional diversity to Ca~V~1.3 channels. Ca~V~1.3~42A~ mRNA is expressed together with Ca~V~1.3~42~ in different mouse and human tissues suggesting that this functional diversity is of physiological relevance to adapt Ca~V~1.3 channel activity for specific physiological needs. Activation at negative voltages is one hallmark of Ca~V~1.3 channels (for review see Ref. [@ref6]) crucial for adequate neurotransmitter release in IHCs and pacemaker function in the SAN, atrioventricular conduction ([@ref30], [@ref31]), and neuronal excitability ([@ref7], [@ref32]). In the absence of the CTM, *V*~0.5,act~ is shifted about 10 mV to more negative voltages by decreasing the slope factor of the activation curve but without measurable effects on the activation threshold. This effect was not correlated with current densities, was independent from cell passage number, and was reproducibly observed for splice variant Ca~V~1.3~42A~ as well as for several truncations mutants. Moreover, it could not be attributed to artificial manipulations of the Ca~V~1.3α1 subunits because it was observed in wild-type channel constructs not modified by fusion to GFP or introduction of other tags. In addition, co-expression of peptides containing the CTM with truncation mutants Ca~V~1.3~ΔC116~, Ca~V~1.3~ΔC158~, and Ca~V~1.3~ΔC473~ reversed this shift. Cells may therefore adjust the activity of Ca~V~1.3-mediated signaling by varying the relative abundance of CTM-containing splice variants.

FIGURE 7.**FRET analysis of the binding of peptide C~158~ or C~116~ to various fragments of the Ca~V~1.3 C terminus.** *N*~FRET~ values obtained from co-expression of CFP-C~158~ or CFP-C~116~ (*probe*) with the indicated YFP-tagged Ca~V~1.3 C-terminal fragments in HEK-293 cells. All constructs showed a homogeneous intracellular distribution. As controls, *N*~FRET~ values are given for CFP co-expressed with YFP-EF-PreIQ-IQ-PCRD (*CFP control*) and YFP with probes CFP-C~158~ (*YFP control 1*) and CFP-C~116~ (*YFP control 2*). Controls are not significantly different from zero (one-sample *t* test against 0). Interaction between fragments was considered when significant difference to both the CFP- and the corresponding YFP control was observed (\*\*\*, *p* \< 0.001, one-way ANOVA followed by Bonferroni post-test).

FIGURE 8.**Tissue expression of Ca~V~1.3 C-terminal splice variants.** Qualitative RT-PCR experiments showing expression of both long (containing exon (*Ex*) 42) and short (containing exon 42A) Ca~V~1.3 isoforms in different mouse (*a*) and human (*b*) tissues. GAPDH was used as a housekeeping gene. One representative out of at least three independent experiments is shown. Quantitative Taqman RT-PCR experiments in *a* (*right*), show the relative expression of exons 42 and 42A in percent of total signal in mouse whole-brain and several brain subregions (\*\*\*, *p* \< 0.001, unpaired Students *t* test, all significantly different from 0, one sample *t* test). Data are given as means ± S.E.

The functional properties of Ca~V~1.3~42~ and Ca~V~1.3~42A~ channels have been studied in previous reports. In two studies functional differences were observed between these splice variants, termed Ca~V~1.3a and Ca~V~1.3b therein, respectively. Calin-Jageman *et al*. ([@ref39]) found that VDF of rat Ca~V~1.3 channels expressed in HEK-293T cells was significantly more pronounced for Ca~V~1.3~42A~ than for Ca~V~1.3~42~ suggesting an autoinhibitory effect of the C-terminal tail on VDF. Comparisons of *I-V* relationship and *I*~Ca~ were not reported in this study. Zhang *et al.* ([@ref37]) expressed hemagglutinin-tagged splice variants in *Xenopus laevis* oocytes and found that *I*~Ba~ of the Ca~V~1.3~42A~ construct was not only larger in amplitude but also its *I-V* relationship was shifted toward more negative voltages, similar to our findings. *I*~Ca~ was not reported. Although a more detailed comparison of the biophysical properties of Ca~V~1.3~42~ and Ca~V~1.3~42A~ was not the purpose of these studies, they support a modulatory role of the C terminus. In contrast, other groups using the corresponding ([@ref5], [@ref13]) or different ([@ref33]) rat Ca~V~1.3~42~ and Ca~V~1.3~42A~ α1 subunit analogues found neither major differences in the activation voltage range nor in CDI ([@ref13]). Therefore, *V*~0.5,act~ and *V*~max~ values for *I*~Ba~ as well as the extent of CDI closely resemble our human Ca~V~1.3~42A~ channels ([@ref5], [@ref13], [@ref12]). Even though at present the molecular basis for this difference is unclear, chimeric constructs between rat and human Ca~V~1.3 constructs expressed under identical experimental conditions (*e.g.* to exclude confounding effects of the heterologous expression system and/or accessory subunit composition) will help to clarify this question.

Our observation of a modulatory C-terminal domain in Ca~V~1.3 adds to recent discoveries of a similar regulatory principle in other LTCC isoforms (see Refs. [@ref15], [@ref17], and references therein). Autoinhibitory control of Ca~V~1.2 channel function was proposed to be based on a binding interaction between a pair of exposed arginine residues and negatively charged residues in α-helical motifs in a proximal (PCRD) and a distal (DCRD) conserved region of the C terminus, respectively ([@ref17]). In our human Ca~V~1.3 channels, 39 residues (1626--1664) comprising the proximal conserved domain containing the PCRD were necessary to confer modulation, as well as FRET to co-expressed CTM-containing peptides. Neutralization of the two conserved positive charges in PCRD did not prevent FRET implying other essential motifs within this 39-residue PCRD domain. Evidence for a role of DCRD comes from the finding that two conserved negative charges are required to support binding of CFP-C~116~ to the upstream domain.

The functional consequences of LTCC C-terminal modulation appear different in Ca~V~1.2 and Ca~V~1.3 channels. In Ca~V~1.2, C-terminal truncation does not induce a more negative *V*~0.5,act~, but overexpression of the distal C terminus shifts the activation range to more positive voltages and reduces the coupling efficiency of voltage-sensing to channel opening ([@ref17]). This is in contrast to Ca~V~1.4 and Ca~V~1.3 channels in which removal of the CTM facilitates activation within a more negative voltage range and CTM co-expression restores gating ([@ref15] and this paper). Differences between LTCCs also exist with respect to the moderation of CDI. Although in both channels the CTM is able to interfere with CaM association, the CTM completely prevents CDI in Ca~V~1.4 ([@ref15]) but only moderates CDI in Ca~V~1.3. To our knowledge the effects of the C-terminal autoinhibitory domain on CDI of Ca~V~1.2 channels has not been systematically analyzed so far.

Our finding of C-terminal modulation of Ca~V~1.3 also raises the important question about potential post-translational proteolytic cleavage in the long C terminus. Such has been reported for Ca~V~1.1 and Ca~V~1.2 channels ([@ref18], [@ref34]). The Ca~V~1.2 cleavage product not only serves as a potent autoinhibitor when it remains noncovalently bound to the channel ([@ref17]) but may also dissociate from the α1 subunit thereby serving as a transcriptional regulator after translocation to the nucleus ([@ref19]). So far biochemical evidence for Ca~V~1.3 C-terminal cleavage is lacking, and it does not appear to function as a transcriptional regulator ([@ref19]). Instead, as demonstrated here, alternative splicing can generate short and functionally distinct Ca~V~1.3 variants. Such splicing has not yet been reported for Ca~V~1.1, Ca~V~1.2, or Ca~V~1.4 channels.

Our data predict that the expression of Ca~V~1.3~42A~ would allow a cell to promote Ca^2+^ entry through Ca~V~1.3 channels at sub-threshold voltages as predicted from the negative shift of the window current ([Fig. 2*e*](#fig2){ref-type="fig"}). Stronger activation at more negative voltages may also facilitate the onset of upstate potentials in neurons. However, during maintained depolarization, the faster CDI would limit Ca^2+^ entry through these channels as relevant in neurons with Ca~V~1.3-dependent pacemaking, *e.g.* dopamine-containing neurons in the substantia nigra ([@ref36]). Whereas negative activation of an even small Ca~V~1.3 current could trigger pacemaking, faster CDI would limit Ca^2+^ entry during ensuing action potentials. This may be important in these neurons that are susceptible to Ca^2+^ toxicity and neuro-degeneration in Parkinson disease ([@ref36]). In contrast, the CTM in Ca~V~1.3~42~ channels may be required for longer lasting Ca^2+^ signals triggered by stronger depolarization inducing cAMP-response element-binding protein phosphorylation and synaptic plasticity ([@ref37]).

Our study raises several important questions that need to be addressed in future studies. The fact that the increase in current density observed in Ca~V~1.3~42A~ channels seems not to be due to increased expression density (and increased gating currents, see [Fig. 2](#fig2){ref-type="fig"}) suggests differences in the unitary current (*e.g.* increase in single-channel conductance or open probability or prolonged open times). Single-channel analysis will also be required to provide a mechanistic explanation for the shift in activation gating parameters in the short Ca~V~1.3 channels. Changes in the unitary conductance of Ca~V~1.2 channels induced by structural alterations within the CaM interaction domains in the C terminus well outside the known pore-forming regions have been described ([@ref38]) providing evidence for a conformational link of the CaM binding domain not only with the gating machinery but also with the channel pore.

Several proteins binding to interaction domains of the C terminus have been described. For example, in neurons the multifunctional PDZ protein Erbin binds to a PDZ-binding domain formed by the last four amino acid residues of Ca~V~1.3~42~ and thereby relieves the autoinhibitory effect of the C terminus on VDF (see Ref. [@ref39] and see above). Also Shank protein ([@ref40]) and RIM-binding protein ([@ref41]) are predicted to bind selectively to the C terminus of Ca~V~1.3 channels and may therefore affect CTM function. The fact that the distal C terminus comprising the CTM also contains regulatory sites, including sites for cAMP-dependent protein kinase phosphorylation ([@ref42]) and AKAP-15 ([@ref43]), raises the interesting possibility that their interference with the activity of the CTM itself could also serve as mechanism to fine-tune Ca~V~1.3 function. Such a mechanism has recently been proposed to explain the still enigmatic mechanism of cAMP-dependent protein kinase-dependent activation of Ca~V~1.2 LTCCs ([@ref35]).

Taken together, we have identified a modulatory domain in Ca~V~1.3 LTCCs responsible for profound differences in the Ca^2+^- and voltage-dependent gating of the different C-terminal splice variants. Given that many unique physiological functions of Ca~V~1.3 depend on the negative activation range of the channel and the amount of Ca^2+^ ions entering during plateau ([@ref7]) or single action potentials ([@ref8]), our findings identify the CTM and factors that modify its activity (such as alternative splicing) as elements suitable to determine electrical excitability. Future experiments must also address the interesting possibility that interference with this C-terminal regulatory mechanism can also be exploited for pharmacological intervention, as an alternative to classical Ca^2+^ channel modulators.
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[^1]: For statistics, *p* \< 0.001 compared with Ca~V~1.3~42A~ (one-way ANOVA followed by Bonferroni post-test).
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[^3]: Values are *p* \< 0.05.
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